Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

Hypothesis: The addition of cemiplimab (PD-1 inhibitor) to standard neoadjuvant chemotherapy in patients with locally advanced HR+ HER2 negative or triple-negative (TN) breast cancer having positive PD-L1 and/or PD-L2 tumor expression will be associated with an increase in pathologic complete response of at least 20%. Primary Objectives: Assess pathologic responses in patients treated with neoadjuvant chemotherapy and cemiplimab.